期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

gp130细胞因子家族在多发性骨髓瘤发病机制中的作用研究进展 被引量：2

原文传递
导出
摘要 糖蛋白130（gp130）是细胞因子受体超家族的成员，一些细胞因子因共享信号转导链gp130而被统称为gp130细胞因子家族，即通常所说的白介素-6（IL-6）细胞因子家族。目前研究发现，gp130细胞因子家族包括IL-6，IL-27，IL-11，睫状神经生长因子（CNTF），白血病抑制因子（LIF）和抑瘤素（OSM）等。研究发现，gp130细胞因子家族与多发性骨髓瘤（MM）发病、预后等密切相关。
作者 夏天 李建平 李文倩(综述) 冯建明(审核)
机构地区 青海大学医学院青海省人民医院血液科
出处 《国际输血及血液学杂志》 CAS 2012年第5期437-441,共5页 International Journal of Blood Transfusion and Hematology
关键词 GP130 细胞因子 多发性骨髓瘤 发病机制
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev, 2010, 24(suppl 1):S5-11.
  • 2Lentzseh S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am, 2007, 21(6).. 1035-1045.
  • 3Gupat M, Han JJ, Stenson M, et al. Elavated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood, 2012, 119(12): 2844-2853.
  • 4Bauer K, Kretzsehmar AK, Cvijic H, et al. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene, 2009, 28(31): 2784-2795.
  • 5Loffler D, Brocke-Heidrich K, Pfeifer G, et al. IL-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 2007, 110(4): 1330-1333.
  • 6Podar K, Chauhan D, Anderson KC, et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009, 23(1) : 10-24.
  • 7Shain KH, Yarde DN, Meads MB, et al. βl-integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells.. implications for microenvironment influence on tumor survival and proliferation. Cancer Res, 2009, 69(3) : 1009-1015.
  • 8Matsushita K, Iwanaga S, Oda T, et al. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest, 2005, 85(10): 1210- 1223.
  • 9付蓉,邵宗鸿.多发性骨髓瘤骨病病理机制研究进展[J].中华血液学杂志,2004,25(2):125-127. 被引量：16
  • 10Giuliani N, Storti P, Bolzoni M, et al. Angiogenesis and multiple myeloma. Cancer Microenviron, 2011, 4(3) : 325 -337.

二级参考文献18

  • 1Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.Semin Oneol, 2001, 28: 551-559.
  • 2Dankbar B, Padre T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell in teractions inmultiple myeloma. Blood, 2000, 95 : 2630-2636.
  • 3Anderson KC. Multiple myeloma. Advances in disease biology:therapeutic implication. Semin Hematol, 2001,38 (2 Suppl 3) : 6-10.
  • 4Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal ceils upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001,15 : 1950-1961.
  • 5Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.Blood, 2003, 101: 2775-2783.
  • 6Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myloma cell growth in the bone marrow milieu.Blood, 2003, 101 : 703-705.
  • 7Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor a in the pathophysiology of human multiple myeloma:therapeutic applications. Oncogene, 2001,20: 4519-4527.
  • 8Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibior PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res, 2002, 62 : 5019-5026.
  • 9MichigamiT,ShimizuN,WilliamsPJ,etal.Cell cellcontactbetweenmarrowstromalcellsandmyelomacellsviaVCAM 1andα4β1 integrinenhancesproductionofosteoclast stimulatingactivity[].Blood.2000
  • 10Hsu H,Lacey D L,Dunstan C R,et al.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[].Proceedings of the National Academy of Sciences of the United States of America.1999

共引文献25

同被引文献24

  • 1张之南,沈悌.血液病诊断及疗效标准[M].3版.北京科学出版社,2007:168.
  • 2Kyle RA, Rajkumar SV. Multiple myeloma[J]. Blood, 2008, 111 : 2962 -2972.
  • 3Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma [J]. Int J Hematol, 2011, 94(4): 310-320.
  • 4Matsushita K, Iwanaga S, OdaT, et al. Interleukin-6/solublein- terleukin 6 receptor complex reduces infarct size via inhibiting myocardial apoptosis[J]. Lab Invest, 2005, 85(10): 1210-1223.
  • 5Andersson G, Ek-Rylander B, Hollberg K, et al. TRACP as anosteopontin phosphatase[J]. J Bone Miner Res, 2003, 18(10): 1912- 1915.
  • 6Yao Nai-shun, Wu Yi-ying, Anthony J. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients [J]. Clinica Chimica Acta, 2011,412:181-185.
  • 7Chen J, Liu W, Lin Q, et al .Vitamin D deficiency and low bone mineral density in native chinese rheumatoid arthritis patients. L1D-10.1111/1756-185X.12160 [J]. Int J Rheum Dis, 2014, 7(1):66-70.
  • 8Tatekoshi A, Sato T, lbata S, et al. Markers of bone metabolism in multiple myeloma patients witched from zoledronic acid to denosumab[J]. Rinsho Ketsueki, 2014, 55(11): 2271-2276.
  • 9Terpos E, Terpos E, Christoulas D, et al. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group[J]. Am J Hematol, 2014, 89(1): 34-40.
  • 10李斯丹,王亚非,邱录贵.多发性骨髓瘤骨病的内科治疗进展[J].中华血液学杂志,2008,29(4):284-286. 被引量：7

引证文献2

二级引证文献5

国际输血及血液学杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部